Pfizer bets $1B cash on the original protein degraders as technology nears prime time

Max Gelman

Senior Editor

As one of the largest multinational corporations in the world, Pfizer has its tendrils in everything. The Big Pharma has potentially hundreds of billions of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer bets $1B cash on the original protein degraders as technology nears prime time

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

US drugs rely heavily on ingredients made overseas, new report shows

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Trump pledges his support for a change to the IRA long sought by drugmakers

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Pfiz­er bets $1B cash on the orig­i­nal pro­tein de­graders as tech­nol­o­gy nears prime time

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Pfizer bets $1B cash on the original protein degraders as technology nears prime time